About 30,000 Europeans die every year from alcohol-related cirrhosis. In its final stages, the disease leads to acute-on-chronic liver failure (ACLF), a syndrome characterised by multi-organ failure. Effective treatment of ACLF is an urgent and unmet need. The A-TANGO consortium performs Phase II clinical studies of an innovative therapeutic strategy that targets inflammation and improves hepatocyte proliferation. We call this novel combinatorial therapy “G-TAK”. In addition, A-TANGO strives to identify reliable biomarkers for better patient stratification and an increased survival rate.
Company Details
- Employees
- 2
- Founded
- -
- Address
- Travessera De Gràcia, 11, 7th Floor,spain
- Industry
- Research
- Website
- https://atango.eu
- Keywords
- hepatology, ACLF, liver disease, liver research, gastroenterology, alcoholic hepatitis, acute-on-chronic liver failure, Toll-like receptor, G-CSF, cirrhosis, TAK242, hepatocyte proliferation, inflammation, biomarkers, alcohol-related cirrhosis, granulocyte colony-stimulating factor, multiorgan failure, late stage clinical trials, Phase 2 clinical trials.
- HQ
- Barcelona, Catalonia
A-Tango Questions
A-Tango's website is https://atango.eu
A-Tango's LinkedIn profile is https://es.linkedin.com/company/a-tango
A-Tango has
2 employees.
View email and phone details for 2
employees at A-Tango.
A-Tango's industry is
Research
A-Tango's top competitors are
Royan رویان,
Newdoor,
International Donor Registry Conference,
European Foundation For The Study Of Chronic Liver Failure (Ef Clif),
Microb-Predict,
Decision-Project,
Royan Education,
Criteria Bio Ventures,
Dkms Stem Cell Bank,
European Liver Patients' Association - Elpa.
A-Tango's categories are Research
A-Tango's founding year is 2021
